PTGS2 and cancer: Moreover, our study demonstrates that the prognostic value of immunohistochemical assessment the stromal COX-2 expression is relatively independent of differences in sensitivities of the primary antibodies if the cut-off thresholds used for defining the cancers overexpressing COX-2 are properly tuned to the sensitivity of the antibodies used for a detection of the enzyme.